ALNY shares fell 5.2% today to $165 after Danielle Brill at Truist Securities downgraded the stock from Buy to Hold and cut the price target to $225, implying 36% downside from current levels. The downgrade reflects widening analyst concern over the KARDIA-3 data. Truist joins a wave of eight analyst firms that cut targets on October 30 alone, including Bernstein's downgrade to Market Perform with a $199 target. The consensus remains Buy at 14 buys versus 9 holds, but the target range has compressed sharply. Goldman Sachs sits at $320 upside, while Bernstein sits 21% below the current price. ALNY is down 35% over the past month and 58.5% year to date following the KARDIA-3 miss in its AL-ATTR cardiomyopathy program.
ALNY downgraded to Hold by Truist; target slashed 29% to $225 from $315.
ALNY shares fell 5.2% today to $165 after Danielle Brill at Truist Securities downgraded the stock from Buy to Hold and cut the price target to $225, implying 36% downside from current levels. The downgrade reflects widening analyst concern over the KARDIA-3 data. Truist joins a wave of eight analyst firms that cut targets on October 30 alone, including Bernstein's downgrade to Market Perform with a $199 target. The consensus remains Buy at 14 buys versus 9 holds, but the target range has compressed sharply. Goldman Sachs sits at $320 upside, while Bernstein sits 21% below the current price. ALNY is down 35% over the past month and 58.5% year to date following the KARDIA-3 miss in its AL-ATTR cardiomyopathy program.
Key data as of 3 Nov 2026
ALNY downgraded to Hold by Truist; target slashed 29% to $225 from $315.
3 Analyst updates in 30 days
ALNY cost to borrow surges to 0.36%, up 136% over one week as availability plummets to 4,656% of short interest.
Alnylam Pharmaceuticals just delivered the worst single-day drop in recent memory, collapsing 28% on July 30 to $205.48 after its earnings print triggered an immediate and sweeping analyst response. The catalyst was…
Alnylam Pharmaceuticals heads into its Q1 2026 earnings today with options traders sending a strikingly bullish signal — the most bullish in at least a year. The put/call ratio dropped to 0.39 on May 19, three standard…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ALNY — free to start on ORTEX.
Sign up for free →Open ALNY on ORTEX